Market Closed -
Nasdaq
04:30:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
2.04
USD
|
+6.25%
|
|
+11.48%
|
+13.65%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
217
|
16.51
|
9.712
|
Enterprise Value (EV)
1 |
202.8
|
6.245
|
43.98
|
P/E ratio
|
-1.48
x
|
-0.4
x
|
-0.44
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
142,816,824
x
|
EV / Revenue
|
-
|
-
|
646,758,000
x
|
EV / EBITDA
|
-7.42
x
|
-0.23
x
|
-2.14
x
|
EV / FCF
|
-16,347,216
x
|
-609,485
x
|
-3,270,432
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
Price to Book
|
33.4
x
|
1.36
x
|
4.35
x
|
Nbr of stocks (in thousands)
|
2,602
|
5,127
|
5,410
|
Reference price
2 |
83.40
|
3.220
|
1.795
|
Announcement Date
|
4/15/22
|
3/20/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
0.068
|
EBITDA
1 |
-16.29
|
-8.857
|
-7.15
|
-27.31
|
-27.07
|
-20.59
|
EBIT
1 |
-16.43
|
-8.878
|
-7.248
|
-27.43
|
-27.23
|
-20.68
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-30,404.41%
|
Earnings before Tax (EBT)
1 |
-18.1
|
-8.937
|
-26.53
|
-122.3
|
-24.53
|
-21.67
|
Net income
1 |
-18.1
|
-8.937
|
-26.53
|
-122.3
|
-24.58
|
-21.67
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-31,864.71%
|
EPS
|
-
|
-
|
-30.17
|
-56.49
|
-8.061
|
-4.081
|
Free Cash Flow
|
-
|
-6.357
|
-6.018
|
-12.4
|
-10.25
|
-13.45
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-19,775.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/2/20
|
10/2/20
|
4/15/22
|
4/15/22
|
3/20/23
|
3/14/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.105
|
-6.296
|
-13.88
|
-8.304
|
Operating Margin
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.458
|
-9.375
|
-3.406
|
-7.311
|
Net income
1 |
-8.479
|
-9.375
|
-3.406
|
-7.316
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-3.400
|
-1.200
|
-2.490
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/15/22
|
7/1/22
|
8/11/22
|
11/14/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
1.27
|
-
|
-
|
34.3
|
Net Cash position
1 |
5.92
|
4.5
|
-
|
14.3
|
10.3
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.1773
x
|
-
|
-
|
-1.664
x
|
Free Cash Flow
|
-
|
-6.36
|
-6.02
|
-12.4
|
-10.2
|
-13.4
|
ROE (net income / shareholders' equity)
|
-
|
-88.9%
|
2,887%
|
4,816%
|
-131%
|
-302%
|
ROA (Net income/ Total Assets)
|
-
|
-35%
|
-31.4%
|
-74.2%
|
-63.3%
|
-36.2%
|
Assets
1 |
-
|
25.56
|
84.58
|
164.8
|
38.86
|
59.87
|
Book Value Per Share
|
-
|
-
|
-13.10
|
2.500
|
2.360
|
0.4100
|
Cash Flow per Share
|
-
|
-
|
1.850
|
6.530
|
2.230
|
1.400
|
Capex
1 |
0.08
|
0.61
|
0.04
|
0.15
|
0.3
|
0.02
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
27.94%
|
Announcement Date
|
10/2/20
|
10/2/20
|
4/15/22
|
4/15/22
|
3/20/23
|
3/14/24
|
|
1st Jan change
|
Capi.
|
---|
| +13.65% | 11.04M | | +55.55% | 59.28B | | +43.17% | 40.94B | | -4.71% | 40.17B | | -5.56% | 28.69B | | +13.76% | 26.63B | | -22.00% | 18.89B | | +31.50% | 12.46B | | +2.16% | 12.42B | | +25.70% | 12.26B |
Other Biotechnology & Medical Research
|